linjc16/ctgov huggingface dataset:
Role of Three Dimensional Ultrasound in the Diagnosis of Septate Uterus

Study Overview
=================
Brief Summary
-----------------
Congenital uterine anomalies are found in 8% of infertile women and 24.5% of infertile women with a history of recurrent miscarriage, with septate and sub-septate uterus being the most common anomalies in these women, Also, septate uterus is the commonest anomaly found in infertile women requiring assisted reproductive technology. Published data showed improved Cumulative pregnancy rate and live birth rate, and a significant reduction in Miscarriage rate in In Vitro Fertilization women after hysteroscopic metroplasty of both small and large septate compared to non-operated women. Investigators hypothesized that trans-vaginal three Dimensional Ultrasound will be superior to Hystro-salpingography for the differentiation between arcuate and septate uterus in infertile women scheduled for In Vitro Fertilization.

Official Title
-----------------
Three Dimensional Trans-vaginal Ultrasound to Reevaluate Arcuate Uteri Diagnosed by Hystro-salpingography

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Radiation: Three dimensional ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women with primary infertility, an indication for IVF and Suspected arcuate or septate uterus diagnosis based on hysterosalpingography . Exclusion Criteria: were confirmed uterine abnormality by prior office hysteroscopy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Three dimensional ultrasound<br>Infertile women with diagnosis of arcuate and septate uterus based on Hystro-salpingography were recruited. All women were examined by Three dimensional ultrasound on day 22 cycle to allow for better delineation of the uterine contour. The outer and inner fundal contours and the length of the fundal notch were examined by Three dimensional ultrasound in the mid-coronal view of the multi-planar and multi-slice display of the uterus. The final diagnosis of the anomalies was based on combined hysteroscopy/laparoscopy examination, the gold standard. | Radiation: Three dimensional ultrasound<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients diagnosed to have subseptate uterus by three dimensional ultrasound |  | 1 year |
Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence

Study Overview
=================
Brief Summary
-----------------
This is a phase 1b study for safety and tolerability of bevacizumab(Avastin)administered into the tumor resection cavity in subjects with Glioblastoma Multiforme (GBM) at first recurrence.

Official Title
-----------------
A Dose-Escalating Phase I Study for Safety and Tolerability of Bevacizumab in Collagen Delivery Vehicle Administered Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence

Conditions
-----------------
Glioblastoma Multiforme

Intervention / Treatment
-----------------
* Drug: Avastin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Recurrent Glioblastoma At least 12 weeks expected survival (KPS >60) 18 years of age or older Able and willing to participate Exclusion Criteria: Any prior diagnosis of any other cancer or other concurrent malignancy. Planned use or current use of other investigation therapy. Systemic autoimmune disease HIV positive Concurrent life threatening disease Impaired organ function Active infection Inadequately controlled hypertension Congestive heart failure Myocardial infection/unstable angina within 6 months Stroke within 6 months Pheripheral vascular disease History of abdominal fistula/gastrointestinal performation Non-healing wound Coagulation disease Known allergy to study treatments Pregnant or lactating

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: bevacizumab (Avastin)<br>Open-label, dose-escalating study conducted in cohorts of 1-3 patients treated at increasing doses of bevacizumab in the dose range of 1-25mg/Ml. A maximum of 24 subjects will be treated in this study (up to 8 cohorts of 3 subjects). | Drug: Avastin<br>* Topical Avastin plus Collagen Sponge placed in surgical cavity after resection of recurrent brain tumor. Dosing range: 0.25 mg/ml - 25 mg/ml.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximum Tolerated Dose of bevacizumab (Avastin) following local administration. |  | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Adverse Events | All adverse events will be recorded in the case report form. | 12 months | 
| Progression Free Survival | Patients will be followed for survival as well as disease progression for 12 months after treatment. | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Brain tumor, GBM, Brain cancer
The Effect of the Alga Dunaliella Bardawil as a Source of 9-cis Retinoic Acid on Lipid Profile in Fibrate Treated Patients.

Study Overview
=================
Brief Summary
-----------------
The effect of fibrates on high density lipoprotein (HDL)-cholesterol levels is suggested to be mediated by its binding to peroxisome proliferator-activated receptor-g (PPARg). Upon ligand binding, PPARg heterodimerizes with the 9-cis retinoic acid receptor (RXR), and the heterodimer regulates gene expression. We assessed the hypothesis that a dual treatment with fibrate plus 9-cis b-carotene-rich powder of the alga Dunaliella bardawil, as a source of 9-cis retinoic acid, would improve the drug's effect on HDL-cholesterol levels. patients with plasma HDL-cholesterol levels below 40 mg/dl and triglyceride (TG) levels above 200 mg/dl after fibrate treatment (for at least 6 weeks). are given four capsules of Dunaliella, providing 60 mg b-carotene/day. The all-trans to 9-cis b-carotene ratio in the capsules is about 1:1.

Official Title
-----------------
The Effect of the Alga Dunaliella Bardawil as a Source of 9-cis Retinoic Acid

Conditions
-----------------
Low HDL Cholesterol

Intervention / Treatment
-----------------
* Drug: Dunaliella


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 18-70 years Fibrate treatment (for at least 6 weeks) HDL-Cholesterol lower than 40mg/dl. Triglyceride over 150mg/dl. Exclusion Criteria: High CPK. Elevated liver functions. Active CHD. Smokers. Diabetes patients treated with Insulin or Avandia. HbA1C great than 8.5.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Dunaliella|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Genetic Risks for Bicuspid Aortic Valve Disease

Study Overview
=================
Brief Summary
-----------------
Bicuspid Aortic Valve (BAV) is the most common congenital heart malformation in adults, but very little is known about the genetic causes or risk factors for adverse outcomes. Currently, it is estimated that most cases of aortic stenosis in patients less than 65 years old are caused by BAVs. BAV patients are also at high risk to develop aneurysms of the ascending aorta, which may lead to aortic dissections. Dr. Prakash and his colleagues plan to use individual genetic information to identify persons with BAV who are at high risk for complications and to customize therapies.

Detailed Description
-----------------
To be included in the study, patients must have a bicuspid or unicuspid aortic valve, documented by clinical history or imaging studies. If the aortic valve was replaced surgically, they may still be eligible. Participants will be asked to donate a single tube of blood and fill out a questionnaire. Patients will also be followed up by telephone or email about once a year to determine if they experience any medical complications related to Bicuspid Aortic Valve (BAV), such as aortic aneurysms, aortic dissections or valve disease. Patients may not be included if they are less than 18 years old at the time of recruitment or have a recognized genetic syndrome or genetic mutation such as Marfan or Ehlers-Danlos syndrome.

Official Title
-----------------
Genetic Risks for Bicuspid Aortic Valve Disease

Conditions
-----------------
Bicuspid Aortic Valve, Unicuspid Aortic Valve

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 18 years of age Diagnosis of bicuspid or unicuspid aortic valve Exclusion Criteria: Less than 18 years of age Recognized syndrome or identified genetic mutation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| BAV Cohort<br>Patients with bicuspid or unicuspid aortic valves, regardless of surgical status. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thoracic aortic aneurysms and dissections | Development of new aneurysms and/or dissections of the thoracic aorta | 10 years | 
| Aortic valve replacement surgery |  | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aortic enlargement | Dilation of thoracic aorta, new or progressive | 10 years |
Laparoscopic/Robotic-assisted Hysteropexy Versus Vaginal Hysterectomy for the Treatment of Uterovaginal Prolapse

Study Overview
=================
Brief Summary
-----------------
objective: aimed to compare laparoscopic/robot-assisted hysteropexy with vaginal hysterectomy for uterine prolapse prospective randomized clinical trial patient 60yrs or more women and POP-Q stage II with symptom or POP-Q III, IV regardless of symptom number of patient: 146 randomize: laparoscopic/robot-assisted hysteropexy vs. hysterectomy follow up: postoperative 1 year primary endpoint: recurrence rate recurrence of uterovaginal prolapse POP-Q stage II-IV recurrence of associated symptom secondary endpoint postoperative 1 year QOL, degree of satisfaction evaluation operative time, estimated blood loss hospitalization period, postoperative pain, return to normal activity

Official Title
-----------------
A Randomized Controlled Study of Laparoscopic/Robotic-assisted Hysteropexy Versus Vaginal Hysterectomy for the Treatment of Uterovaginal Prolapse

Conditions
-----------------
Uterovaginal Prolapse, Hysteropexy

Intervention / Treatment
-----------------
* Procedure: patient who undergo laparoscopic/robotic-assisted hysteropexy
* Procedure: patient who undergo vaginal hysterectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: POP-Q stage II with symptom or POP-Q III, IV regardless of symptom Exclusion Criteria: abnormal uterine bleeding significantly enlarged fibroid uterus postmenopausal uterine bleeding endometrial pathology on tamexifen concomitant medical problems precluding general anesthesia or surgery damaged agreement ability

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: laparoscopic/robotic-assisted hysteropexy<br>patient who undergo laparoscopic/robotic-assisted hysteropexy | Procedure: patient who undergo laparoscopic/robotic-assisted hysteropexy<br> <br> |
| Other: vaginal hysterectomy<br>patient who undergo vaginal hysterectomy | Procedure: patient who undergo vaginal hysterectomy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| recurrence rate (%) | recurrence rate(%) of uterovaginal prolapse POP-Q stage II-IV in postoperative 1 year | postoperative 1 year |
Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction

Study Overview
=================
Brief Summary
-----------------
Purpose of the study is to evaluate the effectiveness and safety of a new investigational dur, IC351. Study is designed to gather information regarding the possible usefulness of IC351 as a treatment of several blood vessel features of scleroderma. This includes Raynaud phenomenon as well as the vaginal dryness and discomfort associated with scleroderma

Official Title
-----------------
Randomized, Placebo-Controlled, Double-Blind, Cross-Over Trial of the Efficacy and Safety of IC351 in Female Patients With Raynaud Phenomenon and Female Sexual Dysfunction Secondary to Systemic Sclerosis

Conditions
-----------------
Systemic Sclerosis

Intervention / Treatment
-----------------
* Drug: Cialis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female with diagnosis of scleroderma Stable sexual relationship with male partner or be sexually active Raynaud phenomenon at least 6 times per week Willing to attempt sexual activity 1/month during study period Exclusion Criteria: Severe internal organ problems related to scleroderma Other gynecologic problems Serious depression Receiving other experimental and Raynaud treatments

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>35 doses of study medication, IC 351 (20 mg) -- crossover to placebo | Drug: Cialis<br>* 35 pills of study medication (20 mg)<br>|
| Experimental: 2<br>35 placebo pills followed with 35 study medication (20 mg) | Drug: Cialis<br>* 35 pills of study medication (20 mg)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Raynaud attacks |  | 16 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
systemic sclerosis, scleroderma, raynaud phenomenon
Cognitive and Health Benefits of Expressive Writing for Family Caregivers Under Stress

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if expressive writing is an effective intervention for reducing stress, enhancing cognition, and improving quality of life for caregivers of older adults with dementia

Detailed Description
-----------------
A significant and growing need exists to support caregivers of older adults with dementia, including methods of support that are easily implemented and targeted at caregivers who can not access multicomponent interventions. The current intervention examines the efficacy of one such approach: expressive writing (EW). We are examining the efficacy of EW, in terms of its ability to reduce stress, enhance cognition, and improve well-being, by comparing it to two control conditions: objective writing about how caregivers spend their time (time management; TM) and objective writing about non-personal historical events (history writing; HW).

Conditions
-----------------
Stress, Psychological, Anxiety

Intervention / Treatment
-----------------
* Behavioral: Expressive Writing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary family caregiver for an older adult with dementia Self-reported caregiver stress or burden Fluency in written/spoken English Exclusion Criteria: non-family or non-primary caregiver existing use of expressive writing / diary

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Expressive Writing|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| General Health Questionnaire |  |  | 
| Impact of Events Scale |  |  | 
| Zarit Burden Interview (short form) |  |  | 
| California Verbal Learning Test |  |  | 
| Ruff 2 & 7 Selective Attention Test |  |  | 
| Wechsler Adult Intelligence Scale (WAIS) |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Expressive Writing, Written Emotional Expression, Caregiver Stress, Cognition
AcuGraph and Digestive Symptoms

Study Overview
=================
Brief Summary
-----------------
This research is designed to study the reliability of the results of an AcuGraph in college students and faculty members with reported digestive symptoms

Detailed Description
-----------------
The specific aim of the study is to test the reliability of the AcuGraph in subjects with irritable bowel syndrome (IBS). The hypothesis is that the AcuGraph will be a reliable method to identify disorders in subjects.

Official Title
-----------------
Can AcuGraph Differentiate Between Participants With and Without Digestive Symptoms

Conditions
-----------------
Digestive Disorders, Irritable Bowel Syndrome, Constipation, Diarrhea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects will be required to answer a questionnaire evaluating for a percentage of digestive disorders disability based on the subject's answers. If a participant's answers do not qualify as a disability, they will be assigned to the asymptomatic group and will still be examined with an AcuGraph to provide normative data. Exclusion Criteria: heart condition kidney disorder thyroid disorders diabetes chronic disease or illness neurological diseases skin or bleeding disorders pregnant currently taking drugs or nutritional supplements pacemaker and/or

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1 Asymptomatic<br>students with conditions being studied | |
| 2 Symptomatic<br>students without conditions being studied | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AcuGraph: computerized device to analyze & document the energetic status of the acupuncture meridians |  | At examination | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IBS Questionnaire |  | At examination |
Topical Betaxolol for the Prevention of Retinopathy of Prematurity

Study Overview
=================
Brief Summary
-----------------
We hypothesize that topical betaxolol will reduce the development of severe retinopathy of prematurity.

Detailed Description
-----------------
The drug is administered twice a day between 32 and 35 weeks gestational age, at a t ime when ROP is most likely to arise.

Official Title
-----------------
Topical Betaxolol for the Prevention of Retinopathy of Prematurity

Conditions
-----------------
Development of Side Effects From Betaxolol

Intervention / Treatment
-----------------
* Drug: Betaxolol
* Drug: topical betaxolol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: <1251 grms birth weight Exclusion Criteria: ocular defect

Ages Eligible for Study
-----------------
Minimum Age: 32 Weeks
Maximum Age: 32 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: betaxolol<br>betaxolol 0.25% 2 per day for 3 weeks | Drug: Betaxolol<br> <br> |
| Placebo Comparator: placebo<br>masked labeling also 2 per day administration | Drug: topical betaxolol<br>* given topically<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| development of apnea and or bradycardia | babies were monitored and HR/RR monitored and recorded by masked observers, periodically | 3 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| development of ROP requiring treatment | Type I ROP was used as a secondary outcome measure | 7 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
betaxolol/ retinopathy of prematurity